Drug General Information |
Drug ID |
D0W3RW
|
Former ID |
DCL000570
|
Drug Name |
MK-2206
|
Drug Type |
Small molecular drug
|
Indication |
Colon cancer; Rectal cancer [ICD9: 153, 154; ICD10:C50]
|
Phase 2 |
[1],
[2]
|
Company |
Merck
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C25H21N5O
|
InChI |
InChI=1S/C25H21N5O/c26-25(12-4-13-25)18-9-7-17(8-10-18)22-19(16-5-2-1-3-6-16)15-20-21(27-22)11-14-30-23(20)28-29-24(30)31/h1-3,5-11,14-15H,4,12-13,26H2,(H,29,31)
|
InChIKey |
ULDXWLCXEDXJGE-UHFFFAOYSA-N
|
PubChem Compound ID |
|
PubChem Substance ID |
56262759, 56394183, 57492690, 103741972, 104148011, 124897541, 124897542, 124897543, 134339130, 134339480, 135692873, 137752525, 137752626, 144116227, 144206919, 152258030, 160645322, 163643092, 164230576, 170466896, 177748733, 180371704, 186009068, 198991166, 202828917, 224709963, 226842086, 248150957, 248783687, 249565628, 251963159
|
Target and Pathway |
Target(s) |
AKT3 protein kinase |
Target Info |
Modulator |
|
KEGG Pathway
|
MAPK signaling pathway
|
ErbB signaling pathway
|
Ras signaling pathway
|
Rap1 signaling pathway
|
cGMP-PKG signaling pathway
|
cAMP signaling pathway
|
Chemokine signaling pathway
|
HIF-1 signaling pathway
|
FoxO signaling pathway
|
Sphingolipid signaling pathway
|
mTOR signaling pathway
|
PI3K-Akt signaling pathway
|
AMPK signaling pathway
|
Apoptosis
|
Adrenergic signaling in cardiomyocytes
|
VEGF signaling pathway
|
Osteoclast differentiation
|
Focal adhesion
|
Tight junction
|
Signaling pathways regulating pluripotency of stem cells
|
Platelet activation
|
Toll-like receptor signaling pathway
|
Jak-STAT signaling pathway
|
T cell receptor signaling pathway
|
B cell receptor signaling pathway
|
Fc epsilon RI signaling pathway
|
Fc gamma R-mediated phagocytosis
|
TNF signaling pathway
|
Neurotrophin signaling pathway
|
Cholinergic synapse
|
Dopaminergic synapse
|
Insulin signaling pathway
|
Progesterone-mediated oocyte maturation
|
Estrogen signaling pathway
|
Prolactin signaling pathway
|
Thyroid hormone signaling pathway
|
Adipocytokine signaling pathway
|
Glucagon signaling pathway
|
Regulation of lipolysis in adipocytes
|
Non-alcoholic fatty liver disease (NAFLD)
|
Carbohydrate digestion and absorption
|
Chagas disease (American trypanosomiasis)
|
Toxoplasmosis
|
Tuberculosis
|
Hepatitis C
|
Hepatitis B
|
Measles
|
Influenza A
|
HTLV-I infection
|
Epstein-Barr virus infection
|
Pathways in cancer
|
Proteoglycans in cancer
|
Colorectal cancer
|
Renal cell carcinoma
|
Pancreatic cancer
|
Endometrial cancer
|
Glioma
|
Prostate cancer
|
Melanoma
|
Chronic myeloid leukemia
|
Acute myeloid leukemia
|
Small cell lung cancer
|
Non-small cell lung cancer
|
Central carbon metabolism in cancer
|
Choline metabolism in cancer
|
NetPath Pathway
|
TSH Signaling Pathway
|
IL2 Signaling Pathway
|
PANTHER Pathway
|
Angiogenesis
|
Apoptosis signaling pathway
|
EGF receptor signaling pathway
|
Endothelin signaling pathway
|
FGF signaling pathway
|
Huntington disease
|
Hypoxia response via HIF activation
|
Inflammation mediated by chemokine and cytokine signaling pathway
|
Interleukin signaling pathway
|
PI3 kinase pathway
|
T cell activation
|
p53 pathway
|
Ras Pathway
|
p53 pathway by glucose deprivation
|
p53 pathway feedback loops 2
|
Pathway Interaction Database
|
S1P3 pathway
|
Class I PI3K signaling events mediated by Akt
|
References |
REF 1 | ClinicalTrials.gov (NCT01249105) MK-2206 for Recurrent Malignant Glioma. U.S. National Institutes of Health. |
---|
REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7945). |